Latest Insider Transactions at Adaptive Biotechnologies Corp (ADPT)
This section provides a real-time view of insider transactions for Adaptive Biotechnologies Corp (ADPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptive Biotechnologies Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptive Biotechnologies Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2020
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
16,680
+0.92%
|
$0
$0.33 P/Share
|
|
Nov 16
2020
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
2,000
-94.43%
|
$96,000
$48.0 P/Share
|
|
Nov 16
2020
|
Robert Hershberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$0
$0.45 P/Share
|
|
Nov 16
2020
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
6,000
-91.84%
|
$282,000
$47.93 P/Share
|
|
Nov 16
2020
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$42,000
$7.8 P/Share
|
|
Nov 16
2020
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
2,000
-92.4%
|
$94,000
$47.94 P/Share
|
|
Nov 16
2020
|
Francis Lo Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$14,000
$7.8 P/Share
|
|
Nov 11
2020
|
Viking Global Performance LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,500,000
-7.46%
|
$122,500,000
$49.52 P/Share
|
|
Nov 11
2020
|
Viking Global Investors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,500,000
-7.46%
|
$122,500,000
$49.52 P/Share
|
|
Nov 09
2020
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,000
-66.39%
|
$1,470,000
$49.74 P/Share
|
|
Nov 09
2020
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+49.18%
|
$180,000
$6.32 P/Share
|
|
Nov 06
2020
|
Lance Baldo Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,250
-93.62%
|
$312,500
$50.9 P/Share
|
|
Nov 06
2020
|
Lance Baldo Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
$43,750
$7.8 P/Share
|
|
Nov 06
2020
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,100
-51.46%
|
$566,100
$51.52 P/Share
|
|
Nov 06
2020
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,100
+48.52%
|
$66,600
$6.32 P/Share
|
|
Nov 05
2020
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,100
-73.29%
|
$555,000
$50.44 P/Share
|
|
Nov 05
2020
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,100
+48.52%
|
$66,600
$6.32 P/Share
|
|
Nov 04
2020
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,100
-74.44%
|
$555,000
$50.59 P/Share
|
|
Nov 04
2020
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,100
+48.52%
|
$66,600
$6.32 P/Share
|
|
Nov 02
2020
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
6,772
-92.07%
|
$304,740
$45.81 P/Share
|
|
Nov 02
2020
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
6,772
+34.03%
|
$40,632
$6.79 P/Share
|
|
Oct 26
2020
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,880
-39.14%
|
$141,120
$49.54 P/Share
|
|
Oct 26
2020
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,880
+30.64%
|
$20,160
$7.18 P/Share
|
|
Oct 19
2020
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
417
-100.0%
|
$21,267
$51.25 P/Share
|
|
Oct 19
2020
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
417
+50.0%
|
$2,502
$6.27 P/Share
|
|
Oct 16
2020
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,100
-94.24%
|
$566,100
$51.79 P/Share
|
|
Oct 16
2020
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,100
+48.52%
|
$66,600
$6.32 P/Share
|
|
Oct 15
2020
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$102,000
$51.51 P/Share
|
|
Oct 15
2020
|
Francis Lo Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$14,000
$7.8 P/Share
|
|
Oct 15
2020
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$102,000
$51.51 P/Share
|
|
Oct 15
2020
|
Robert Hershberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$0
$0.45 P/Share
|
|
Oct 15
2020
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,100
-94.24%
|
$566,100
$51.55 P/Share
|
|
Oct 15
2020
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,100
+48.52%
|
$66,600
$6.32 P/Share
|
|
Oct 14
2020
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
12,000
-69.37%
|
$624,000
$52.78 P/Share
|
|
Oct 14
2020
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+50.0%
|
$84,000
$7.8 P/Share
|
|
Oct 14
2020
|
Michael J Pellini Director |
SELL
Open market or private sale
|
Direct |
50,000
-78.26%
|
$2,600,000
$52.42 P/Share
|
|
Oct 14
2020
|
Michael J Pellini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$300,000
$6.55 P/Share
|
|
Oct 14
2020
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,100
-74.18%
|
$577,200
$52.36 P/Share
|
|
Oct 14
2020
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,100
+48.52%
|
$66,600
$6.32 P/Share
|
|
Oct 12
2020
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
25,000
-100.0%
|
$1,300,000
$52.8 P/Share
|
|
Oct 12
2020
|
Francis Lo Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$175,000
$7.8 P/Share
|
|
Oct 08
2020
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,000
-81.41%
|
$1,500,000
$50.91 P/Share
|
|
Oct 08
2020
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+49.18%
|
$180,000
$6.32 P/Share
|
|
Oct 08
2020
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
24,260
-0.67%
|
$1,213,000
$50.97 P/Share
|
|
Oct 08
2020
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
24,260
+1.33%
|
$0
$0.33 P/Share
|
|
Oct 07
2020
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
50,000
-1.37%
|
$2,450,000
$49.8 P/Share
|
|
Oct 07
2020
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+2.66%
|
$0
$0.33 P/Share
|
|
Oct 06
2020
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
18,280
-0.51%
|
$895,720
$49.41 P/Share
|
|
Oct 06
2020
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
18,280
+1.01%
|
$0
$0.33 P/Share
|
|
Oct 06
2020
|
Lance Baldo Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,250
-83.89%
|
$306,250
$49.37 P/Share
|